Literature DB >> 6971114

Some pharmacokinetic properties and bioavailability by oral and rectal route of piroxicam in rodents and in man.

P Schiantarelli, D Acerbi, G Bovis.   

Abstract

In a comparative study on rodents and on man the fundamental pharmacokinetic properties of 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide (piroxicam) were assessed and the bioavailability of the drug after oral and rectal administration was determined. It was found that: the plasma half-life is much longer in man (ca. 35 h) than in rodents (3--5.5 h in the rabbit, 5 h in the rat and mouse). The long plasma disappearance time in man is attributed to the relatively strong binding with the plasma proteins. A thorough pharmacokinetic analysis in the rabbit revealed a two-compartment distribution of the drug with an intercompartmental t 1/2 0.67 h and an excretion + metabolisation t 1/2 of 3.16 h. The extremely low excretion of the drug as such or as the glucuronide in the bile and urine suggests that the main excretion route is metabolic. The rectal bioavailability is similar to the oral bioavailability both in rabbit and rat and in man. Comparison of the AUC after i.v. injection with the AUCs after oral and rectal administration in the rabbit seems to show that absorption by rectal and oral route is quantitative.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6971114

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  10 in total

1.  Comparative bioavailability of two different rectal preparations of piroxicam in man.

Authors:  S Benkö; G Grézal; E Nagy; I Klebovich
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Oral bioavailability of CHF1194, an inclusion complex of piroxicam and beta-cyclodextrin, in healthy subjects under single dose and steady-state conditions.

Authors:  X Deroubaix; A Stockis; A M Allemon; E Lebacq; D Acerbi; P Ventura
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

3.  Plasma protein binding and interaction studies with piroxicam.

Authors:  Z Trnavská; K Trnavský
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-08       Impact factor: 3.000

4.  The influence of cholestyramine on the elimination of tenoxicam and piroxicam.

Authors:  T W Guentert; R Defoin; H Mosberg
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

6.  Incidence of gastric ulcers by indomethacin and piroxicam in rats.

Authors:  C N Aguwa
Journal:  Arch Toxicol       Date:  1985-01       Impact factor: 5.153

Review 7.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

8.  Binding of piroxicam to synovial fluid and plasma proteins in patients with rheumatoid arthritis.

Authors:  Z Trnavská; K Trnavský; D Zlnay
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.

Authors:  R K Verbeeck; J L Blackburn; G R Loewen
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

Review 10.  Piroxicam: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-09       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.